Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Formulation buffer Clear all
Completed Phase 1 Interventional

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

NCT07090824
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions
Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

NCT04381468
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pepinemab, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 2, 2026, 10:22 AM EDT
Not listed Not applicable Interventional

Surgiphor vs Saline Joints

NCT05434260
View directory record Official record
Conditions
Prosthetic-joint Infection
Interventions
Surgiphor Irrigation Solution, Sterile saline
Device
Lead sponsor
Center for Innovation and Research Organization
Network
Eligibility
18 Years and older
Enrollment
868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Baltimore, Maryland • Columbia, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

NCT03815916
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
30 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 2, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis

NCT01999192
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tregalizumab, Placebo
Drug
Lead sponsor
Biotest
Industry
Eligibility
18 Years to 75 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Paradise Valley, Arizona • Springfield, Illinois • Lincoln, Nebraska + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 2, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Dose Regimen Study of SLI-F06 in Healthy Volunteers

NCT05501327
View directory record Official record
Conditions
Scar, Wound Healing
Interventions
SLI-F06
Drug
Lead sponsor
Scarless Laboratories, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Encinitas, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

NCT02481674
View directory record Official record
Conditions
Huntington's Disease
Interventions
VX15/2503, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
21 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

NCT00044707
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

NCT02440035
View directory record Official record
Conditions
Healthy Participants
Interventions
Ad35.RSV.FA2, Ad26.RSV.FA2, Placebo
Biological · Drug
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 2, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination

NCT06007183
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
CHIKV VLP vaccine booster, Placebo booster
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
12 Years and older
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
24
States / cities
Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Safety of Intravenous Artesunate

NCT00292942
View directory record Official record
Conditions
Malaria, Malaria, Cerebral
Interventions
Intravenous Artesunate, Placebo
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 2, 2026, 10:22 AM EDT
Withdrawn Phase 2 Interventional

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)

NCT03843710
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT02277197
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
Interventions
Ficlatuzumab, Cetuximab
Drug
Lead sponsor
James J Lee
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Buffered vs. Unbuffered Local Anesthesia in Mandibular Molars Diagnosed With Symptomatic Irreversible Pulpitis

NCT05227300
View directory record Official record
Conditions
Symptomatic Irreversible Pulpitis
Interventions
Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution, 2% lidocaine with 1:100,000 epinephrine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Furoscix in Heart Failure Patients With Diuretic Resistance

NCT05528588
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix, Diuretic Therapy
Combination Product · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 2, 2026, 10:22 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

NCT07142278
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
Interventions
DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only)
Biological
Lead sponsor
Nuravax, Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 10:22 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

NCT03191383
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Newton, Kansas • Syracuse, New York • Ellensburg, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Women With Metastatic Breast Cancer

NCT00849459
View directory record Official record
Conditions
Breast Cancer
Interventions
adenovirus-mediated human interleukin-12
Biological
Lead sponsor
Max Sung
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of CJCV2 With and Without ALFQ

NCT05500417
View directory record Official record
Conditions
Campylobacter Infection
Interventions
ALFQ, CJCV2
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

NCT02561871
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Infections
Interventions
Ad26.RSV.FA2, Ad35.RSV.FA2, Placebo
Biological · Drug
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults

NCT06444048
View directory record Official record
Conditions
Enterovirus Infection
Interventions
EV68-228-N, Placebo for EV68-228-N
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

NCT05072080
View directory record Official record
Conditions
Chikungunya Virus
Interventions
CHIKV VLP/adjuvant, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
12 Years to 64 Years
Enrollment
3,258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
47
States / cities
Huntsville, Alabama • Mobile, Alabama • Tempe, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Sep 2, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic

NCT01861457
View directory record Official record
Conditions
Infectious Disease
Interventions
Nozin® Nasal Sanitizer®, Placebo
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 2, 2026, 10:22 AM EDT